Phase 3 Stroke Trial, Recruiting NCT06561867 Sponsor: Kafrelsheikh University Condition: Stroke
Back to Stroke

Phase 3 Stroke Trial, Recruiting

NCT06561867
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are between 18 and 75 years old (any gender)
  • You have had your first-ever moderate or moderately severe stroke caused by a blood clot in the brain
  • You started antiplatelet medication (blood-thinning tablets) within the first 24 hours of your stroke symptoms beginning
  • You are not eligible for clot-dissolving treatment (called rt-PA or thrombolysis)
  • You have previously had a mini-stroke (TIA) — this does not automatically exclude you

Who may not be able to join:

  • You were not able to be followed up for 90 days after joining the trial
  • Your stroke symptoms were very mild or very severe based on a standard stroke scoring scale, or your symptoms cleared up quickly before scan results were available
  • You have a known ongoing or recurring brain or nervous system condition, such as epilepsy, multiple sclerosis, a brain tumour (meningioma), or a previous head injury that left lasting neurological effects
  • You had a seizure (fit) at the time your stroke began
  • You have signs of major organ failure, an active cancer, or you had a heart attack within the last six weeks
  • You were taking warfarin, regularly taking ticagrelor in the week before admission, or received chemotherapy within the past year
  • You have an active stomach ulcer, have had stomach or bowel surgery, have had any bleeding episode in the past year, or had major surgery within the last three months
  • You have a known allergy to the medications being studied
  • Certain blood test or vital sign results on admission are outside acceptable ranges, including blood clotting levels, blood sugar, blood pressure, or platelet count (confirm with trial site)
  • You are pregnant or breastfeeding
  • Your stroke was caused by a blood clot in a vein (venous thrombosis), followed a cardiac arrest, or was linked to a severe drop in blood pressure
  • You have any other reason you cannot safely take the study medications

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 2 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Kafrelsheikh University
Registry
ClinicalTrials.gov
Start date
30 August 2024
Est. completion
30 November 2025

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

rate of new stroke; Rate of drug-related hemorrhagic complications

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 2 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov